- Home
- BDRX vs SLRX Comparison
BDRX vs SLRX Comparison
Compare BDRX & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- SLRX
- Stock Information
- Founded
- BDRX 2000
- SLRX N/A
- Country
- BDRX United Kingdom
- SLRX United States
- Employees
- BDRX N/A
- SLRX N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- SLRX Health Care
- Exchange
- BDRX Nasdaq
- SLRX Nasdaq
- Market Cap
- BDRX 5.8M
- SLRX 1.8M
- IPO Year
- BDRX N/A
- SLRX N/A
- Fundamental
- Price
- BDRX $0.87
- SLRX $0.75
- Analyst Decision
- BDRX
- SLRX
- Analyst Count
- BDRX 0
- SLRX 0
- Target Price
- BDRX N/A
- SLRX N/A
- AVG Volume (30 Days)
- BDRX 3.1M
- SLRX 3.6M
- Earning Date
- BDRX 04-11-2025
- SLRX 08-08-2025
- Dividend Yield
- BDRX N/A
- SLRX N/A
- EPS Growth
- BDRX N/A
- SLRX N/A
- EPS
- BDRX N/A
- SLRX N/A
- Revenue
- BDRX N/A
- SLRX N/A
- Revenue This Year
- BDRX N/A
- SLRX N/A
- Revenue Next Year
- BDRX N/A
- SLRX N/A
- P/E Ratio
- BDRX N/A
- SLRX N/A
- Revenue Growth
- BDRX N/A
- SLRX N/A
- 52 Week Low
- BDRX $0.78
- SLRX $0.45
- 52 Week High
- BDRX $41.50
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- BDRX 38.67
- SLRX 41.73
- Support Level
- BDRX $0.85
- SLRX $0.66
- Resistance Level
- BDRX $0.92
- SLRX $0.90
- Average True Range (ATR)
- BDRX 0.06
- SLRX 0.12
- MACD
- BDRX 0.01
- SLRX -0.03
- Stochastic Oscillator
- BDRX 32.73
- SLRX 16.46
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.